Sarepta Therapeutics stock plummeted Monday after the company said a second patient receiving its gene therapy died from ...

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

By Christy Santhosh and Bhanvi Satija (Reuters) -Shares of Sarepta Therapeutics slumped 36% in premarket trading on Monday after the company reported the death of a second patient in three months who ...

Sarepta’s shares crashed 41% in pre-market trading Monday morning to $21.01 after the biotech reported a second death from ...

Muscular dystrophy refers to a group of rare, genetic, progressive diseases that primarily affect the body’s muscles, causing ...